Stockreport

Foghorn Therapeutics GAAP EPS of -$1.18 misses by $0.08, revenue of $30.91M misses by $0.31M [Seeking Alpha]

Foghorn Therapeutics Inc.  (FHTX) 
PDF As of December 31, 2025, the Company had $158.9 million in cash, cash equivalents and marketable securities, providing cash runway into the first half of 2028. Fresh [Read more]